Linked Life Data

7569285

Source:http://linkedlifedata.com/resource/pubmed/id/7569285

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7-8
pubmed:dateCreated
1995-11-21
pubmed:abstractText
In chronic steatosic liver disease, alcohol or non-alcohol related or HBV, HCV, HDV associated, a reduction in hepatic glutathione and, consequently, in the detoxifying effects of hepatocytes is observed. Intravenous administration of high dose glutathione in patients with chronic steatosic liver disease has shown that glutathione significantly improves the rate of some hepatic tests (bilirubin, GOT, GPT, GT) even several months after treatment interruption. Further confirmation of the efficacy of GSH treatment is provided by the reduction of malondialdehyde, a marker of hepatic cell damage. The optimal results obtained in patients receiving 1800 mg/die/i.v. advocate the use of this high dosage.
pubmed:language
ita
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0034-1193
pubmed:author
pubmed:issnType
Print
pubmed:volume
86
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
290-3
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
[Glutathione in the treatment of chronic fatty liver diseases].
pubmed:affiliation
Istituto Policattedra, Università, Bari.
pubmed:publicationType
Journal Article, Comparative Study, English Abstract